Beacon Pharmaceuticals PLC (DSE: BEACONPHAR)
Bangladesh
· Delayed Price · Currency is BDT 125.20
+11.30 (9.92%)
At close: Sep 9, 2024
Beacon Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 | 2018 - 2014 |
| Revenue | 9,893 | 8,510 | 8,023 | 7,121 | 5,591 | 4,647 | Upgrade
|
| Revenue Growth (YoY) | 20.79% | 6.07% | 12.66% | 27.37% | 20.31% | 23.56% | Upgrade
|
| Cost of Revenue | 4,905 | 4,251 | 3,906 | 3,452 | 2,724 | 2,374 | Upgrade
|
| Gross Profit | 4,987 | 4,259 | 4,116 | 3,669 | 2,867 | 2,273 | Upgrade
|
| Selling, General & Admin | 3,643 | 3,291 | 2,499 | 2,307 | 2,533 | 1,959 | Upgrade
|
| Operating Expenses | 3,643 | 3,291 | 2,499 | 2,307 | 2,533 | 1,959 | Upgrade
|
| Operating Income | 1,344 | 967.7 | 1,617 | 1,362 | 333.47 | 314.44 | Upgrade
|
| Interest Expense | -1,011 | -460.92 | -337.96 | -164.82 | -149.33 | -152.64 | Upgrade
|
| Interest & Investment Income | 3.65 | 3.65 | 0.32 | 3.24 | 1.31 | 1.27 | Upgrade
|
| Currency Exchange Gain (Loss) | 2.68 | 2.68 | 0.5 | - | - | 1.22 | Upgrade
|
| Other Non Operating Income (Expenses) | 183.16 | 145.96 | 9.81 | -1.98 | -0.95 | -0.89 | Upgrade
|
| EBT Excluding Unusual Items | 522.62 | 659.07 | 1,290 | 1,198 | 184.5 | 163.4 | Upgrade
|
| Gain (Loss) on Sale of Investments | 16.94 | 16.94 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 3.07 | 3.07 | 3.04 | - | - | - | Upgrade
|
| Pretax Income | 542.62 | 679.07 | 1,293 | 1,198 | 184.5 | 163.4 | Upgrade
|
| Income Tax Expense | 76.64 | 169.23 | 357.93 | 334.99 | -196.19 | 45.7 | Upgrade
|
| Net Income | 465.98 | 509.84 | 935.04 | 863.17 | 380.69 | 117.7 | Upgrade
|
| Net Income to Common | 465.98 | 509.84 | 935.04 | 863.17 | 380.69 | 117.7 | Upgrade
|
| Net Income Growth | -33.32% | -45.47% | 8.33% | 126.74% | 223.44% | -6.66% | Upgrade
|
| Shares Outstanding (Basic) | 231 | 231 | 231 | 231 | 231 | 231 | Upgrade
|
| Shares Outstanding (Diluted) | 231 | 231 | 231 | 231 | 231 | 231 | Upgrade
|
| Shares Change (YoY) | 0.00% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 2.02 | 2.21 | 4.05 | 3.74 | 1.65 | 0.51 | Upgrade
|
| EPS (Diluted) | 2.02 | 2.21 | 4.05 | 3.74 | 1.65 | 0.51 | Upgrade
|
| EPS Growth | -33.32% | -45.47% | 8.33% | 126.74% | 223.44% | -6.66% | Upgrade
|
| Free Cash Flow | -3,559 | -1,193 | -637.07 | -116.85 | -22.8 | -23.16 | Upgrade
|
| Free Cash Flow Per Share | -15.41 | -5.17 | -2.76 | -0.51 | -0.10 | -0.10 | Upgrade
|
| Dividend Per Share | - | 1.600 | 1.600 | 1.500 | - | 0.500 | Upgrade
|
| Dividend Growth | - | 0% | 6.67% | - | - | -16.67% | Upgrade
|
| Gross Margin | 50.42% | 50.05% | 51.31% | 51.52% | 51.28% | 48.91% | Upgrade
|
| Operating Margin | 13.59% | 11.37% | 20.16% | 19.12% | 5.96% | 6.77% | Upgrade
|
| Profit Margin | 4.71% | 5.99% | 11.65% | 12.12% | 6.81% | 2.53% | Upgrade
|
| Free Cash Flow Margin | -35.98% | -14.02% | -7.94% | -1.64% | -0.41% | -0.50% | Upgrade
|
| EBITDA | 1,923 | 1,487 | 2,057 | 1,747 | 844.48 | 863.37 | Upgrade
|
| EBITDA Margin | 19.44% | 17.47% | 25.64% | 24.53% | 15.10% | 18.58% | Upgrade
|
| D&A For EBITDA | 578.33 | 518.92 | 439.7 | 385.16 | 511.01 | 548.93 | Upgrade
|
| EBIT | 1,344 | 967.7 | 1,617 | 1,362 | 333.47 | 314.44 | Upgrade
|
| EBIT Margin | 13.59% | 11.37% | 20.16% | 19.12% | 5.96% | 6.77% | Upgrade
|
| Effective Tax Rate | 14.12% | 24.92% | 27.68% | 27.96% | - | 27.97% | Upgrade
|
| Advertising Expenses | - | 69.04 | 68.5 | 52.97 | 1,004 | 644.28 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.